ATNM vs NVX vs RNAC vs CBAT

For growth investors, CBAK Energy Technology, Inc.

(CBAT) is the stronger pick with -13. 6% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). CBAK Energy Technology, Inc. (CBAT) offers the better valuation at 6. 0x trailing P/E, making it the more compelling value choice. Analysts rate Cartesian Therapeutics, Inc. (RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CBAK Energy Technology, Inc.

(CBAT) delivered a total return of -81. 0%, compared to -96. 9% for Novonix Limited (NVX). Over 10 years, the gap is even starker: CBAT returned -69. 9% versus RNAC's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CBAK Energy Technology, Inc.

(CBAT) is the lower-risk stock at 1. 05β versus Cartesian Therapeutics, Inc. 's 2. 03β — meaning RNAC is approximately 94% more volatile than CBAT relative to the S&P 500. On balance sheet safety, Actinium Pharmaceuticals, Inc. (ATNM) carries a lower debt/equity ratio of 5% versus 51% for Novonix Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CBAK Energy Technology, Inc.

(CBAT) is pulling ahead at -13. 6% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: CBAK Energy Technology, Inc. grew EPS 574. 5% year-over-year, compared to -52. 6% for Cartesian Therapeutics, Inc.. Over a 3-year CAGR, CBAT leads at 49. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CBAK Energy Technology, Inc.

(CBAT) is the more profitable company, earning 6. 7% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CBAT leads at 5. 0% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CBAK Energy Technology, Inc.

(CBAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CBAT: -69. 9%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ATNM (Healthcare) and NVX (Industrials) and RNAC (Healthcare) and CBAT (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ATNM is a small-cap quality compounder stock; NVX is a small-cap quality compounder stock; RNAC is a small-cap quality compounder stock; CBAT is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.